The "Defending Affordable Prescription Drug Costs Act" aims to prohibit discriminatory practices against 340B covered entities and their contract pharmacies by health insurers, pharmacy benefit managers, and pharmaceutical manufacturers. The act specifically prohibits these entities from establishing lower reimbursement rates for 340B drugs compared to non-340B drugs based solely on the drug's 340B status, imposing different fees or conditions on reimbursement based on 340B status, denying or limiting participation in pharmacy networks based on 340B status, and interfering with a 340B covered entity's choice to use a contract pharmacy for drug distribution or dispensing.

Additionally, the act restricts pharmaceutical manufacturers from denying, restricting, prohibiting, or interfering with the acquisition and dispensing of 340B drugs by contract pharmacies.

The act also establishes annual reporting requirements for 340B covered entities, which must submit a report detailing their participation in the federal 340B program, including financial data related to drug acquisition and payments, the use of savings for community benefits, and any material breaches or changes in eligibility status.

Violations of this act will be considered violations of chapter 13.1 of title 6 regarding unfair sales practices. The provisions of this act will take effect on October 1, 2025.